Status:
COMPLETED
Plasm Gastrin Concentrations in Response to Nexium Administration in Healthy Volunteers
Lead Sponsor:
City of Hope Medical Center
Conditions:
Healthy
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
This dose response study is proposed to explore the extent to which Nexium increases endogenous gastrin concentrations and to assess whether Nexium treatment may be useful in the setting of islet cell...
Detailed Description
Islet transplantation has been shown to effectively treat type 1 diabetes by stabilizing blood glucose control while reducing/eliminating the need for exogenous insulin injections. However, for reason...
Eligibility Criteria
Inclusion
- age 18-65
- healthy
- free of clinical signs of diabetes, peptic ulcer, liver or kidney disease,autoimmune disease, or any acute chronic infection.
Exclusion
- history or clinical signs of diabetes
- history of liver or kidney disease
- positive H-pylori status
- currently using a proton pump inhibitor
- prior hypersensitivity to Nexium
- pregnant or breastfeeding women
Key Trial Info
Start Date :
March 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2012
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT01135472
Start Date
March 1 2010
End Date
April 1 2012
Last Update
December 18 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
City of Hope Medical Center
Duarte, California, United States, 91010